Although RoxyBond is not the first abuse-deterrent oxycodone immediaterelease (IR) product, it is different. In April 2017, RoxyBond gained FDA approval based on manufacturer claims that the drug has qualities that are effective against nasal or intravenous (IV) abuse. The approval was not unanimous, however, especially on the question of whether the formulation could significantly deter IV abuse of the drug.
The development of abuse-deterrent formulations for IR Class II (CII) drugs could be very significant. Because these medications are far more prescribed and abused than extended-release (ER) versions, offering an abuse-deterrent IR product could have a huge effect on prescription drug diversion. [Read more…]